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Leukotrienes (LTs), both LTB4 and the cysteinyl LTs (CysLTs) LTC4, LTD4 and LTE4, are implicated in a wide
variety of inﬂammatory disorders. These lipid mediators are generated from arachidonic acid via
multistep enzymatic reactions through which arachidonic acid is liberated from membrane phospho-
lipids through the action of phospholipase A2. LTB4 and CysLTs exert their biological effects by binding to
cognate receptors, which belong to the G protein-coupled receptor superfamily. LTB4 is widely consid-
ered to be a potent chemoattractant for most subsets of leukocytes, whereas CysLTs are potent bron-
choconstrictors that have effects on airway remodeling. LTs play a central role in the pathogenesis of
asthma and many other inﬂammatory diseases. This review will provide an update on the synthesis,
biological function, and relevance of LTs to the pathobiology of allergic diseases, and examine the current
and future therapeutic prospects of LT modiﬁers.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
In addition to their primary role as a source of nutrients, lipids
are the major components of cell membranes. Lipid derivatives
such as prostaglandins (PGs) and leukotrienes (LTs) function as
signaling molecules and play pivotal roles in inﬂammatory and
immune responses. LTs are divided into two classes, namely, the
chemoattractant LTB4, which only carries hydroxyl moieties, and
the cysteinyl LTs [CysLTs: LTC4, LTD4, and LTE4],1,2 which also carry
amino acid moieties. LTs are generated from arachidonic acid via
the 5-lipoxygenase (5-LO) pathway and are representative lipid
mediators or bioactive lipids. LTs exert their biological effects by
binding to G protein-coupled receptors (GPCRs).3 Different LT re-
ceptor subtypes exert unique functions.4 LTs are involved in various
inﬂammatory diseases, including asthma, allergic rhinitis, atopic
dermatitis, allergic conjunctivitis, rheumatoid arthritis, chronic
obstructive pulmonary disease, obliterative bronchiolitis after lung
transplantation, and interstitial lung diseases.5 This review pro-
vides an overview of recent ﬁndings related to the synthesis of LTs
and their cognate receptors, examines their relevance to the
pathobiology of allergic diseases, and discusses both current and
future therapeutic prospects.y, Juntendo University School
1, Japan.
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ety of Allergology.
rgology. Production and hosting by ElsOverview of the 5-LO pathway
Arachidonic acid is released from the sn-2 position of mem-
brane phospholipids by phospholipase A2 in response to various
biological stimuli6,7 and subsequently metabolized by the cyclo-
oxygenase (COX) and lipoxygenase (LO) pathways to generate PGs
and LTs, respectively.8 There are at least six different types of
mammalian lipoxygenase, which are named according to the car-
bon position at which a single oxygen molecule is incorporated.
Among them, 5-LO, expressed mainly in granulocytes, macro-
phages andmast cells, is the most widely studied one.9 Arachidonic
acid is ﬁrst oxidized at the C-5 position by the dual enzymatic ac-
tivity of 5-LO to yield 5-hydroxyperoxyeicosatetraenoic acid (5-
HpETE) followed by an unstable intermediate, leukotriene A4
(LTA4); 5-HpETE acts in concert with 5-LO-activating protein (FLAP)
in a Ca2þ dependent manner.10,11 LTA4 is either converted to LTB4 by
LTA4 hydrolase12e16 or conjugated to reduced glutathione by
leukotriene C4 synthase (LTC4S) to yield CysLT (LTC4).17e19 LTC4 is
then exported from the cell and converted to LTD4 and LTE4, the
most stable CysLTs, by extracellular peptidases (Fig. 1). A trans-
cellular mechanism that generates CysLTs has also been reported.20
Cells containing 5-LO, but not LTC4S (e.g., neutrophils), release LTA4,
which is then used by other cells that express LTC4S but not 5-LO
(e.g., platelets or endothelial cells). This mechanism of trans-
cellular biosynthesis is important for generating high concentra-
tions of CysLTs in the local environment.
Studies of mouse models of different inﬂammatory diseases,
such as platelet-activating factor (PAF)-induced shock, arachidonicevier B.V. All rights reserved.
Fig. 1. The arachidonic acid cascade generates leukotrienes from membrane phospholipids. PLA2, phospholipase A2; COX, cyclooxygenase; 5-LOX, 5-lipoxygenase; FLAP, 5-
lipoxygenase activating protein; 5-HPETE, 5-hydroperoxyeicosatetraenoic acid. The names of the enzymes are given in the boxes.
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nitis, and ovalbumin-induced airway inﬂammation, show that mice
deﬁcient in 5-LO are unable to synthesize detectable levels of LTs
and thus display reduced levels of inﬂammation.21e24 Mice deﬁ-
cient in LTA4 hydrolase, which is required for the production of
LTB4, show similarly reduced responses after the induction of
zymosan-induced peritonitis and PAF-induced shock.25
A competitive inhibitor of the 5-LO enzyme, zileuton, the only
agent that can inhibit the production of LT, has been approved for
the treatment of asthma.26e31 Recent studies report that a nM
LTC4S inhibitor, the synthesis of which was based on the crystalstructure of the enzyme, shows potential for future drug develop-
ment.32,33 Finally, FLAP inhibitors (MK-886, MK-0591, BAY X1005,
and DG-031) have been developed and appear to show
promise.34e39
LTB4 and its receptors
LTB4 was ﬁrst identiﬁed as a potent mediator of leukocyte
function by Ford-Hutchinson and colleagues,40 who showed that it
was chemotactic for neutrophils, and this ﬁnding was further
conﬁrmed by Palmer et al.41 Nowadays, LTB4 is widely considered
Table 1
Pathophysiological roles of LTB4, BLT1 and BLT2 in allergic diseases.
Respiratory system Bronchial asthma 44,45,79,80,87e89,95,96
 development of airway hyperresponsiveness
 migration of eosinophils, DCs, and IL-13
producing Th2 cells
 neutrophil inﬂux
Exercise-induced asthma 98,99
 bronchoconstriction
Aspirin-sensitive asthma 100
 monocyte activation
Allergic rhinitis 104
 neutrophil activation
Skin Atopic dermatitis 109,114,118,119
 neutrophil, eosinophil, Th2 cell inﬂux
 TNFa-induced CCL27 production in
keratinocytes
 itching induction
Eye Allergic conjuntivitis 120,121,126
 mast cell and neutrophil inﬂux
 eosinophil inﬂux
 ocular scratching
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phils, macrophages, monocytes, eosinophils, and dendritic
cells.42,43 LTB4 plays crucial roles in inﬂammatory and immune
responses by activating phagocytic cells, differentiated T-cells, and
dendritic cells.44,45
LTB4 is inactivated via metabolic degradation through the
microsomal u-oxidation, mitochondrial, and peroxisomal b-
oxidation pathways.2,46,47 LTB4 u-hydroxylase (cytochrome P450
family 4F3; CYP4F3) catalyzes the conversion of LTB4 to 20-hydroxy
LTB4 in neutrophils and hepatocytes, and then sequentially con-
verts it to 20-carboxy LTB4. Another important inactivation
pathway involves the conversion of LTB4 to 12-keto LTB4 by 12-
hydroxyeicoanoid dehydrogenase.48,49
LTB4 exerts its biological effects through two GPCRs that are
expressed on the surface of cells. These receptors are the high-
afﬁnity LTB4 receptor, BLT1,50 and the low afﬁnity LTB4 receptor,
BLT2.51,52 The genes that encode these receptors are located in very
close proximity to each other in the genomes of humans and mice.
LTB4 was once thought to be a ligand for the nuclear hormone re-
ceptor, peroxisome proliferator-activated receptor alpha (PPARa)53;
however, high doses of LTB4 are required to activate PPARa.
Although BLT1 is a high-afﬁnity receptor for LTB4, it can also be
activated by 20-OH-LTB4, 12-oxo-LTB4, 12-epi-LTB4, 20-COOH-LTB4,
12(R)-HETE, and 20-hydroxyl LTB4 (albeit at higher concentrations
than LTB4).50,54 BLT2 exhibited LTB4 binding with a 20-fold higher
Kd, and calcium signaling with a 30-fold higher EC50 value,
compared with BLT1.49 In addition to LTB4, several lipoxygenase
products including 12(S)-HETE, 12(S)-HpETE, and 15(S)-HETE
activate BLT2.54 A recent study identiﬁed 12(S)-hydroxyheptadeca-
5Z, 8E,10E-trienoic acid (12-HHT), a downstreammetabolite of COX
enzymes, as the endogenous ligand for BLT2.55 The crystal struc-
tures of these two LTB4 receptors are yet to be resolved.
The open reading frame of the human LTB4R gene encodes a
BLT1 protein comprising 352 amino acid residues (NCBI Reference
Sequence: NP_858043). BLT1 proteins from other species share
relatively high sequence homology with human BLT1: 78% for
mouse,42 78% for guinea pig,56 and 80% for rat BLT1.57 The BLT2
protein comprises 358 amino acids (NCBI Reference Sequence:
NP_062813) and shows 36e45% amino acid identity with human
BLT1.51,52 BLT2 is highly conserved; indeed, murine BLT2 shows 92%
homology with human BLT2 at the amino acid level.58
BLT1 is predominantly expressed on leukocytes, including
granulocytes, monocytes, macrophages, eosinophils, dendritic
cells, mast cells, and differentiated T-cells.43 Functional BLT1 is also
expressed on non-myeloid cells, including vascular smooth muscle
cells, endothelial cells, skeletal muscle satellite cells, and neural
stem cells.59e62 Mouse BLT2 is primarily expressed on epidermal
keratinocytes and intestinal tissues,58,63 whereas human BLT2 is
ubiquitously expressed throughout the body.51,52
The downstream transduction of intracellular signals mediated
by BLT1 and BLT2 involves intracellular Ca2þ mobilization and in-
hibition of adenylyl cyclase.64 Several studies show that BLT1 and
BLT2 couple to Gi- and/or Gq-proteins, depending on the particular
cell type.50,52,64e66 These two GPCRs activate various kinases,
which, in turn, phosphorylate downstream signaling molecules,
e.g., extracellular signal-regulated kinases (ERKs),67 phosphoino-
sitide-3-OH kinase (PI3K), and Akt.65,66 BLTRs also activate the NF-
kB signaling pathway.59,63,68e70 Pathophysiological roles of LTB4
and its cognate receptors, BLTRs are listed in Table 1.
LTB4 and asthma
Asthma is a complex and chronic disorder of the airways that is
characterized by airﬂow obstruction, allergic airway inﬂammation,
and airway hyperresponsiveness (AHR). Airway inﬂammation playsa critical role in the pathogenesis of asthma, characterized by the
inﬁltration of inﬂammatory cells such as neutrophils, eosinophils,
and lymphocytes. Studies performed in asthmatic patients suggest
an important role for LTB4; indeed, increased levels of LTB4 are
detected in sputum, bronchoalveolar lavage (BAL) ﬂuid, urine,
exhaled breath condensate (EBC), and arterial blood samples from
asthmatic patients.71e76 Increased LTB4 synthesis, caused by the
upregulation of 5-LO and LTA4 hydrolase, has been reported in both
adult and pediatric asthma patients,77,78 and in patients with
neutrophil-induced sputum triggered by PAF79; however, the real
role of LTB4 in asthma is still unclear. In contrast to the broncho-
constriction mediators (CysLTs), LTB4 is thought to be a proin-
ﬂammatory mediator that is responsible for the recruitment,
activation, and survival of leukocytes, including neutrophils and
eosinophils.80e82 The accumulation of neutrophils and eosinophils
is a pathological parameter in asthma patients. Massive numbers of
neutrophils are present in the airways of asthmatic patients who
suffer clinical exacerbations or asthma-related sudden death.83,84
Eosinophilic inﬂammation of the airways correlates with disease
severity, and these cells are likely to play a central role in the
epithelial damage associated with asthma.85 Studies of eosinophil-
deﬁcient mice have revealed a pathological role for these cells.86
The high-afﬁnity receptor for LTB4, BLT1, also plays a role in
asthma. BLT1-deﬁcient mice are resistant to OVA-induced allergic
AHR and show reduced accumulation of lymphocytes, eosinophils,
and dendritic cells in the lungs.44,87e89 In accordance with a mouse
model of allergic pulmonary inﬂammation, high numbers of BLT1-
expressing effector memory CD8þ T-cells are present in BAL ﬂuid
from asthmatic patients.90,91 A clinical trial of the BLT receptor
antagonist, LY293111, in 12 asthmatic patients showed that it led to
a signiﬁcant reduction in the number of neutrophils in the BAL, but
failed to improve lung function or airway reactivity after allergen
challenge.92 Studies of a guinea pig asthma model showed that
LY293111 had no effect on eosinophil and macrophage inﬁltration
into the BAL.93 However, a study examining the role of another BLT1
antagonist, CP-105,696, in monkeys showed that the compound
inhibited LTB4-mediated neutrophil chemotaxis and the upregu-
lation of CD11bþ cells in the BAL, leading to decreased AHR.94 In
addition, BLT2 signaling may play a role in antigen-induced allergic
asthma, as evidenced by the therapeutic effect of the BLT2 antag-
onist, LY255283, or an antisense BLT2 on murine airway inﬂam-
mation and AHR.95 By contrast, a recent study in BLT2-deﬁcient
mice indicated that BLT2 plays a protective role in allergic airway
inﬂammation, and that reduced BLT2 expression by CD4þ T-cells
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depth studies are needed to clarify the role of LTB4 in the patho-
physiology of asthma.
LTB4 and exercise-induced asthma and aspirin-sensitive asthma
Exercise-induced asthma (EIA) is a clinical condition charac-
terized by bronchoconstriction that lasts for 30e90 min after a
short period of exercise.97 LTB4 production by neutrophils stimu-
lated by unopsonized zymosan and a calcium ionophore increases
after EIA.98 Exercise-induced stress increases the transcription of
genes encoding 5-LO and FLAP, thereby increasing the production
of LTB4 and LTC4 in plasma after exercise; this suggests that LTB4
and CysLTs may play critical roles in EIA. Importantly, several 5-LO
inhibitors, including ABT-761, suppress exercise-induced broncho-
constriction. This effect appears to be related to the inhibition of
LTB4 release.99
Aspirin-sensitive asthma (ASA) is a particular phenotype of se-
vere late-onset asthma, which is accompanied by rhinosinusitis
and nasal polyposis. CysLTs are thought to play a central role in the
mechanism(s) underlying ASA; however, other studies show that
LTB4 is involved in ASA. The release of LTB4, but not LTC4, from
calcium ionophoreestimulated peripheral blood monocytes
(PBMCs) increases in patients with ASA.100
LTB4 and allergic rhinitis
Symptoms of allergic rhinitis, including itching, sneezing, rhi-
norrhea, and nasal obstruction can coexist with, and have an effect
on, bronchial asthma. Numerous studies report that patients with
allergic rhinitis have increased levels of LTB4 in the nasal cavity and
EBC,101e103 suggesting a role for LTB4 in the pathogenesis of allergic
rhinitis. Peripheral blood neutrophils isolated from patients with
allergic rhinitis produce more LTB4 after calcium ionophore stim-
ulation than those isolated from healthy controls.104 However,
treatment with zileuton, selective histamine receptor H1 antago-
nists, or petasol butenoate complex (Ze 339) reduces the amount of
LTB4 in nasal lavage ﬂuid from patients with allergic
rhinitis.30,105,106
LTB4 and atopic dermatitis
Atopic dermatitis (AD) is a chronic, relapsing skin condition that
affects more than 2% of the population; however, the pathophysi-
ology of AD is not well understood. Immunologic abnormalities and
the subsequent release of inﬂammatory mediators appear to play a
crucial role in AD. Glucocorticoids have long been the gold standard
treatment, but their use is limited by their adverse side effects.107
Several mediators of AD are released upon mast cell degranula-
tion during the late phase of a type I allergic reaction, which then
induce cellular inﬁltration, leading to more persistent symp-
toms.108 Recent data reveal that both LTB4 and CysLTs are crucial for
the pathogenesis of AD, as follows: LTB4 initiates the inﬁltration of
neutrophils, eosinophils, and Th2 cells into the skin; CysLTs then
induce the characteristic structural alterations associated with
chronically affected skin, speciﬁcally skin ﬁbrosis and keratinocyte
proliferation.109 Indeed, a number of studies report increased levels
of LTB4 in the skin lesions of patients with AD or allergic contact
dermatitis.110e112 The activity of LTA4 hydrolase, which catalyzes
the conversion of LTA4 to LTB4, in peripheral blood poly-
morphonuclear leukocytes (PMNs) and PBMCs parallels disease
severity in AD patients.113 LTB4 also increases TNF-alpha-induced
CCL27 production by human keratinocytes in the skin lesions of
those with AD or allergic contact dermatitis.114A study of dogs with AD showed that there was a signiﬁcant
increase in the median level of LTB4 production by PMNs compared
with that in control animals.115 A similar study revealed a signiﬁ-
cant increase in 5-LO and FLAP expression in both non-lesional and
lesional skin compared with that in healthy skin.116
LTB4 is a potent mediator of itching. In AD mice, scratching
triggers skin ﬂares that result in neutrophil inﬂux and, ulti-
mately, severe allergic skin inﬂammation, all of which are largely
dependent on the LTB4/BLT1 axis. Allergic skin inﬂammation in
response to the epicutaneous application of ovalbumin to tape-
stripped skin is severely impaired in BLT1-deﬁcient mice.117 In
mice, the itch-eliciting activity of sphingosylphosphorylcholine is
mediated by the direct action of LTB4 produced by keratino-
cytes.118 NC/Nga mice with AD-like skin lesions show a signiﬁ-
cant increase in LTB4 levels in the lesional skin; however, topical
application of the BLT1 antagonist, ONO-4057, inhibits sponta-
neous itch-related behavior.119 Taken together, these studies
suggest that the LTB4/BLT1 axis plays a critical role in AD and may
provide a promising pharmacological target for the treatment of
this disease.
LTB4 and allergic conjunctivitis
Ocular itching, lacrimation, and redness are frequent symptoms
suffered by patients with allergic conjunctivitis, a condition usually
considered as a comorbidity associated with allergic rhinitis. A
hallmark of allergic conjunctivitis is an inﬂux of mast cells and
neutrophils, which release histamine, LTs, matrix metal-
loproteinases, PGs, and inﬂammatory cytokines.120 LTB4 was ﬁrst
shown to cause eosinophil migration into conjunctival tissue in a
guinea pig model.121 Combination treatment with an H1-receptor
antagonist and a 5-LO inhibitor resulted in near-complete sup-
pression of allergic conjunctivitis in this model.122 Nathan et al. ﬁrst
reported increased LTB4 levels in the tears of patients with vernal
conjunctivitis (VKC).123 Topical treatment with drugs such as
lodoxamide, a mast cell membrane stabilizer, is effective at
reducing LTB4 and LTC4 levels in patients with VKC and ocular
prosthesis-associated giant papillary conjunctivitis.124,125 A recent
study in a mouse model showed that the BLT1 antagonist, ONO-
4057, inhibited ocular scratching induced by ragweed pollen chal-
lenge.126 In addition to histamine, LTB4 is involved in the patho-
genesis of allergic conjunctivitis, suggesting that the therapeutic
use of H1 receptor antagonists (which inhibit LTB4) or the com-
bined use of H1 and BLT1 antagonists may be more effective
treatments for this condition.
CysLTs and their receptors
CysLTs, namely LTC4, LTD4, and LTE4 (known historically as
“slow-reacting substance of anaphylaxis”127), are primary inﬂam-
matory lipid mediators of several inﬂammatory diseases, including
asthma and allergic rhinitis. CysLTs are produced predominantly by
eosinophils, mast cells, and macrophages in response to a variety of
stimuli.128
CysLTs are in activated via three major mechanisms, as follows:
the formation of N-acetyl derivatives of LTE4, reaction with hypo-
chlorous acid to form sulfoxide and LTB4, and u-oxidation and b-
elimination to form shortened metabolites.
CysLTs exert their effects via cell-surface receptors, which are
mainly classiﬁed into two major subtypes: CysLT1 and CysLT2
(both of which are GPCRs). CysLT1 is sensitive to classical antag-
onists such as montelukast, zaﬁrlukast, pranlukast, pobilukast, and
MK571, whereas CysLT2 mediates several effects that are not
inhibited by classical antagonists.129 One compound, BAYu9773,
antagonizes both CysLT1 and CysLT2 receptors; however, it is
Table 2
Pathophysiological roles of CysLTs, CysLT1 and CysLT2 in allergic diseases.
Respiratory system Bronchial asthma 151e153, 158e160,162e164,170
 bronchoconstriction
 development of airway hyperresponsiveness
 eosinophil and neutrophil inﬂux
 edema
 goblet cell metaplasia
 decreased mucociliary clearance
 epithelial hypertrophy
 subepithelial collagen deposition
 smooth muscle proliferation
 vascular permeability
Exercise-induced asthma & Aspirin-sensitive asthma 97
 bronchoconstriction
Allergic rhinitis 185
 vascular permeability
 mucus production and secretion
 inﬂammatory cell inﬂux
Skin Atopic dermatitis 196
 skin ﬁbrosis
 collagen deposition
Eye Allergic conjuntivitis 197
 mucin secretion by goblet cells
Systemic disorder Anaphylaxix 170, 200e202
 mast cell activation
 vascular permeability
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human tissues.130 A recent report suggests that BAYu9773 partially
agonizes CysLT2.131
Recent molecular cloning and functional studies of these two
receptors have provided new insights into their biological func-
tion(s). The human CysLT1 gene is located on the X chromosome
(Xq13-Xq21) and encodes a protein of 337 amino acids.132,133 Hu-
man and mouse CysLT1 share approximately 87% homology at the
amino acid level.131 The gene encoding human CysLT2 is located on
chromosome 13q14, the open reading frame of which encodes a
protein of 347 amino acids.134,135 The homology between human
and mouse CysLT2 is 65%, and between human and rat CysLT2 is
73%. Interestingly, the two human receptor subtypes are only 31%
identical at the amino acid level.131
The rank order afﬁnities of CysLTs (as determined by the effects
of increasing Ca2þ concentration) in HEK 293 and COS cells trans-
fectedwith CysLT receptors is LTD4 > LTC4> LTE4 for CysLT1132,133,136
and LTD4 ¼ LTC4 > LTE4 for CysLT2.131,134,135,137
When human CysLT1 mRNA was expressed in normal lung
smooth muscle cells and interstitial macrophages, little or no
expression was detected in normal airway epithelial cells by in
situ hybridization.132 CysLT1 expression was also detected in eo-
sinophils, monocytes, macrophages, and pre-granulocytic CD34þ
cells isolated from normal peripheral blood.138 Human cord-
blood-derived mast cells also express CysLT1, but not CysLT2.139
Mouse CysLT1 shows an expression pattern different from that
of human CysLT1, as it is expressed predominantly in the lungs
and skin.136
In humans, CysLT2 is expressed at high levels by spleen and
peripheral blood leukocytes, as well as in coronary smooth muscle
cells, endothelial cells, Purkinje ﬁber cells, and human umbilical
vein endothelial cells (HUVEC).134,135,137,140 Uniquely, this receptor
is also expressed in the heart, adrenal gland, and the brain. Indeed,
CysLT2 is widely expressed in the brain and spinal cord.134,135 The
expression of CysLT1 in HUVEC is induced by cytokines such as IL-
1b.141 Eosinophils express higher levels of CysLT2 than CysLT1,142
and CysLT2 expression is further increased by priming the cells
with IL-4.143 Taken together, these ﬁndings suggest that the
expression of CysLT receptors is regulated by various cytokines, the
expression of which is intimately associated with the pathogenesis
of many allergic diseases.
Studies of intracellular signaling pathways show that CysLT re-
ceptors couple only to Gq/11 family proteins (at least in Xenopus
laevis oocytes injected with CysLT1 cDNA or HEK-293 cells trans-
fected with CysLT1) because pertussis toxin did not inhibit LTD4-
induced functional responses in these cells.132,133 However, CysLT1
couples to both Gq/11 and Gi/0 family proteins in differentiated hu-
man U937 cells, intestinal 407 cells, and human monocytic leuke-
mia THP-1 cells144e147; thus the CysLT-signaling pathways seem to
be dependent on both the cell type and the availability of trimeric G
proteins.148
One study suggests the presence of additional CysLT receptor
subtypes in human tissues because a single CysLT failed to acti-
vate a CysLT receptor and the dual antagonist BAYu9773 failed to
antagonize all CysLT functional responses.149 More recently,
GPR99, previously thought to be a GPCR for oxoglutarate (Oxgr1),
was found to bind preferentially to LTE4 (at least in the Cysltr1/
Cysltr2 double knockout mouse).150 GPR99 is now known as
CysLT3. Because LTE4 is the most abundant CysLT present at sites
of inﬂammation, the discovery of this new CysLT receptor pro-
vides a novel avenue for studies of physiological and pathological
conditions related to allergic diseases. Further experiments are
required to conﬁrm that GPR99 is indeed CysLT3. Pathophysio-
logical roles of CysLTs and its cognate receptors are listed in
Table 2.CysLTs and asthma
CysLTs are thought to play a pivotal role in the pathogenesis of
acute and chronic asthma because they are the most potent bron-
choconstrictors in humans; indeed, they are thousands of times
more potent than histamine.151 The marked vasoconstriction ef-
fects of LTC4 and LTD4 on isolated human bronchi were ﬁrst
described by Dahlen et al., in 1980.152 More recently, their bron-
choconstricting effects have been conformed in healthy human
subjects.153 Allergen challenge of lung tissue taken from asthmatic
patients induces bronchial contraction, which correlates with the
release of CysLTs.128 CysLTs have also been detected in blood, BAL
ﬂuid, and urine samples from asthmatic patients after
bronchospasm.71e73,75,76,154 Both 5-LO and LTRAs (leukotriene re-
ceptor antagonists) have clinical beneﬁts when used to treat pa-
tients with asthma.155,156
CysLTs exert a wide range of biological activities that contribute
to the pathogenesis of asthma. Activated CysLT1 acts as an impor-
tant mediator of eosinophilic inﬂammation by up-regulating the
expression of endothelial adhesion molecules, inducing eosinophil
chemotaxis and reducing eosinophil apoptosis.151 Moreover, eo-
sinophils are thought to be themain cellular source of CysLTs. These
cells express CysLT1 on the membrane, suggesting that this mole-
cule has autocrine activity.148 When compared with a placebo,
treatment with LTRA induces a marked reduction in the number of
eosinophils in the peripheral blood and sputum.157 Additionally, 5-
LO-deﬁcient mice with antigen-induced AHR exhibited a 50%
reduction in the number of airway eosinophils.24
A number of studies show that the mechanism underlying the
function of CysLTs in asthma is based upon CysLT-dependent
exacerbation of mucosal edema caused by increased vascular
leakage,158,159 increased mucus production by goblet cells,160 and
decreased mucociliary clearance.161
CysLTs also play a role in airway remodeling by promoting the
proliferation of airway smooth muscle cells and epithelial cells, and
by increasing collagen deposition (an important feature of chronic
asthma).162 Studies conducted in smooth muscle-speciﬁc human
CysLT1-transgenic mice show that the severity of allergen-induced
AHR is markedly increased upon LTD4 challenge.163 The inherent
tone of the human airway is thought to result from a balance
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and vasodilators, such as prostaglandin E2.165 CysLTs increase the
production of certain cytokines and vice versa. The LTRA, pranlu-
kast, signiﬁcantly reduces the production of IL-4, IL-5, and GM-CSF
by PBMCs upon allergen induction.166 These cytokines, in turn,
stimulate the secretion of more cytokines, increase adhesion
molecule expression by eosinophils, and promote eosinophil sur-
vival through CysLT1.167,168
CysLT1 is believed to be responsible for the majority of CysLT-
mediated effects in asthma because such effects can be reversed
by treatment with CysLT1 antagonists.169 A role of CysLTs/CysLT1 in
the clinical manifestations of asthma is supported by the ﬁnding
that LTRAs (montelukast, zaﬁrlukast, and pranlukast) are an effec-
tive treatment for asthma, in addition to the 5-LO inhibitor, zileu-
ton.149 On the other hand, the role of CysLT2 in asthma remains
largely unknown because there is no current speciﬁc antagonist.
However, a transgenic mouse model overexpressing human CysLT2
in endothelial cells has been used to investigate the effect of CysLT2
on endothelial integrity and blood pressure regulation. The results
showed that vascular permeability increased after exposure to
CysLTs.170
CysLTs and EIA and ASA
As discussed before, CysLTs play a role in EIA; furthermore,
several studies show that the concentration of CysLTs is high in the
airways of patients with EIA.171 The levels of CysLTs in EBC from EIA
subjects were higher than control ones, and they increased after
exercise challenge; moreover, the change in CysLT levels in EBC
upon exercise challenge was strongly correlated with disease
severity.172
Oral challenge with aspirin induces bronchoconstriction in 19%
of adult asthma patients.173 ASA comprises the clinical triad of
asthma, chronic rhinosinusitis, and nasal polyps, and is induced by
aspirin and other NSAIDs, but not by COX-2 selective in-
hibitors.174,175 The levels of CysLTs in the urine and exhaled air of
ASA patients increase and are further augmented by aspirin
challenge.176e179 Also, the expression of LTC4 synthase is markedly
increased in bronchial biopsy and mucosal eosinophils from ASA
patients when compared with non-aspirin-sensitive asthmatic
patients or normal subjects.180,181 In addition, the number of
CysLT1-expressing nasal inﬂammatory leukocytes increased in ASA
patients compared with non-aspirin-sensitive asthmatic patients,
and down-regulation of the receptors is observed after desensiti-
zation to aspirin.104 Although overproduction of CysLTs is a hall-
mark of ASA, the underlying mechanism is still poorly understood.
A recent study suggests that platelet-adherent leukocytes
contribute to the overproduction of CysLTs in ASA patients,182 and
aspirin is reported to directly trigger the activation of eosinophils
andmast cell.183 The 5-LO inhibitor, zileuton, which is a leukotriene
pathway inhibitor, controls ASA symptoms by inhibiting aspirin-
induced bronchoconstriction, strongly suggesting the involve-
ment of leukotrienes in the pathogenesis of ASA.184
CysLTs and allergic rhinitis
Allergic rhinitis is believed to share a common pathophysiology
and immunopathology with asthma, and is also a major risk factor
for the development of asthma.185 Most of the cells involved in the
pathophysiology of allergic rhinitis produce and release CysLTs.148
There is an increase in LTC4 levels in the nasal secretions of
allergic rhinitis patients after nasal antigen exposure, which cor-
relates well with nasal symptoms.186,187 Granulocytes isolated from
such patients release more LTC4 and LTB4 than those from healthy
subjects.188 Moreover, severe nasal obstruction in patients withseasonal allergic rhinitis is associated with increased excretion of
urinary LTE4.189 The detailed mechanisms by which CysLTs and
their cognate receptors promote allergic rhinitis are thoroughly
reviewed by Peters-Golden et al.185 CysLTs enhance vascular
permeability, leading to nasal congestion, increased mucus pro-
duction and secretion, rhinorrhea, and the recruitment of inﬂam-
matory cells into the tissues. A growing body of evidence suggests
that patients with allergic rhinitis respond favorably to treatment
with CysLT receptor antagonists.190
CysLTs and AD
The pathophysiology of AD is not well understood and the role
of CysLTs in the condition is unclear. Several studies report
increased levels of LTE4 in the urine of AD patients, which are
associated with disease exacerbation.191,192 High LTC4 levels are
detected in extracts from skin lesions and in the serum of AD pa-
tients, and levels decrease as the disease becomes less severe.193
Despite the fact that LTRAs are generally recommended for
asthma patients with moderate to severe AD,194 one clinical study
reported that treating AD patients with montelukast had no
beneﬁcial effect compared with a placebo.195 A recent study
showed that eosinophil-derived LTC4 and CysLT2 are critical for
promoting skin ﬁbrosis and increased collagen deposition in a
mouse model of AD.196 More studies are needed to clarify the
precise role of CysLTs in the pathogenesis of AD.
CysLTs and allergic conjunctivitis
One of the main mechanisms underlying the pathogenesis of
allergic conjunctivitis is increased secretion of mucin by goblet
cells; this mucin is then carried to the ocular surface in tears. Both
CysLT1 and CysLT2 are expressed in rat conjunctiva and in cultured
rat and human conjunctival goblet cells. Treatment with the CysLT1
receptor antagonist, MK571, or resolvins leads to a signiﬁcant
reduction in the amount of CysLT1 secreted by LTD4-stimulated rat
and human goblet cells.197 A clinical trial of orally administered
montelukast in patients with VKC and asthma reported a reduction
of the severity of ocular signs and symptoms.198 In addition,
conjunctival epithelium expresses abundant CysLT receptors,
whereas the other goblet cell-containing epithelia express few or
no such receptors.197
CysLTs and anaphylaxis
Anaphylaxis is a life-threatening allergic reaction that occurs
when an antigen binds to immunoglobulin E and activates mast
cells and basophils, leading to the release of inﬂammatory media-
tors.199 The resulting increase in vascular permeability is one of the
key events in anaphylaxis. Increased LTE4 levels are associated with
anaphylaxis. Mast cells are thought to be the main source of CysLTs
during anaphylactic reactions.200,201 Compared with that in wild-
type mice, extravasation of plasma proteins is reduced in CysLT1-
deﬁcient mice undergoing IgE-mediated passive cutaneous
anaphylaxis.202 Furthermore, the vascular permeability response to
endogenous CysLTs produced by activatedmast cells during passive
cutaneous anaphylaxis is increased in CycLT2 transgenic mice.170
Both of these animal studies suggest that CysLT receptors play a
role in regulating endothelial integrity.
Conclusions
Studies conducted over the past 50 years suggest that LTs play
crucial roles in the pathogenesis of asthma and a number of other
allergic diseases. Our knowledge of the biological role(s) of LTs in
M. Liu, T. Yokomizo / Allergology International 64 (2015) 17e26 23inﬂammatory conditions will continue to improve due to a better
understanding of how LT synthesis is regulated, the identiﬁcation of
mechanisms underlying the functions of the receptors that mediate
responses to LTs, and the development of novel therapeutic agents
for allergic diseases.Conﬂict of interest
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